SV Health Investors

SV Health Investors, formerly SV Life Sciences, is a leading healthcare and life sciences venture capital and growth equity firm. Their goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. With over $2 billion in capital under management in seven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.

Houman Ashrafian

Managing Partner Biotech UK

Alex Badamchi-Zadeh

Biotech UK

Michael H. Balmuth

Managing Partner Healthcare Growth USA

Laurence Barker

Partner Dementia UK

Jonathan Behr

Partner Dementia USA

Kate Bingham

Managing Partner Biotech UK

Elizabeth Blake

Investment Associate

Daniel D. Burgess

Venture Partner Biotech USA

Hamish Cameron

Venture Partner

Elizabeth Campbell

Entrepreneur in Residence

Rebecca Canter

Associate Dementia UK

Michael G. Carter

Venture Partner

Bruce A. Cerullo

Operating Partner Healthcare Growth USA

Ailsa Craig

Investment Manager Public Equities UK

Carl L. Culicchia

VP

Lucy Costa Duarte

Head of Investor Relations Public Equities UK

Charles Dunn

Associate Biotech UK

Brent Faduski

CFO Biotech, Healthcare Growth, Medtech USA

Thomas J. Flynn

Managing Partner Healthcare Growth USA

William Gerard

Analyst Healthcare Growth USA

Tillman Gerngross

Venture Partner Biotech USA

James D. Glynn

Venture Partner

David Guyer

Venture Partner Biotech USA

Eugene D. Hill

Chairman Healthcare Growth USA

Carl Harald Janson

Investment Manager

Jack Kenney

Associate Biotech USA

Paul LaViolette

Managing Partner and COO Medtech USA

Megan MacDonagh

Senior Associate Medtech USA

Greg Madden

Managing Partner Medtech, Healthcare Growth USA

Denise Marks

Partner, Chief Administrative Partner and Chief Compliance Officer

Niyoshi Patel

Associate Dementia USA

Marek Poszepczynski

Investment Manager Public Equities UK

Michael J. Ross

Managing Partner Biotech USA

Barbara Tate

Venture Partner Dementia USA

348 past transactions

Rheostat Therapeutics, Inc.

Private Placement in 2018
Rheostat Therapeutics, Inc., a biotech company, engages in the discovery of treatments for neurodegeneration, cognition, and rare diseases. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.

Avitide, Inc.

Series C in 2016
Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

Atopix Therapeutics Limited

Venture Round in 2016
Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis. Its lead candidate is currently being studied in a Phase 2 clinical trial for moderate to severe atopic dermatitis in several leading European dermatology centres.

Sutro Biopharma, Inc.

Venture Round in 2007
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Alector

Private Placement in 2018
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

CHF Solutions

Venture Round in 2005
CHF Solutions manufactures innovative medical devices for cardiac care. Its mission is to provide medical practitioners with practical solutions that enable the treatment of patients with unmet clinical needs. CHF Solutions was founded in 1998 and is based in Brooklyn Park, Minnesota.

Maestro Health

Series A in 2016
Founded in 2013, Maestro Health is an American employee benefits company that provides integrated one-stop shopping experiences, along with private-labeled exchange solutions. It also offers employee health and benefits management solutions for brokers, small employers, and Fortune 1000 organizations. It combines private exchange, benefits administration, enrollment, self-insurance, healthcare savings account administration, and components on its integrated mobile and web platform, maestroEDGE. The company owns and operates a proprietary private exchange and medical TPA, which allows the streamlined integration of care management to drive down costs for employers.

Juvaris BioTherapeutics

Series B in 2010
Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.

Affinium Pharmaceuticals

Series B in 2011
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.

AqueSys

Series D in 2014
AqueSys, Inc., an ophthalmic company, focuses on innovating and commercializing implantable devices that improves the treatment of glaucoma. It offers XEN, a gel stent that creates a diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The company’s XEN gel stent creates a new pathway to allow the excess fluid in eyes to flow out, and lowers the eye pressure. AqueSys, Inc. was incorporated in 2005 and is based in Aliso Viejo, California. As of October 16, 2015, AqueSys, Inc. operates as a subsidiary of Allergan plc.

Bicycle Therapeutics

Series A in 2016
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Catamaran Bio

Series A in 2020
Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Direct Flow Medical

Venture Round in 2016
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

Artios Pharma

Private Placement in 2018
Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

Spinal Kinetics LLC

Series B in 2006
Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

Confluent Surgical

Series D in 2005
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

EBR Systems

Series D in 2011
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

Good Start Genetics

Debt Financing in 2016
Good Start Genetics, Inc., a molecular diagnostics company, provides genetic screening of inherited diseases. It offers EmbryVu, a preimplantation genetic screening test to improve in vitro fertilization by identifying embryos for the implantation and pregnancy. The company was founded in 2007 and is based in Cambridge, Massachusetts. As of August 4, 2017, Good Start Genetics, Inc. operates as a subsidiary of Invitae Corporation.

Avitide, Inc.

Series C in 2015
Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

CSA Medical

Venture Round in 2019
CSA Medical provides cryotherapy systems. It offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues, as well as transports liquid nitrogen that is passed through a standard endoscope. CSA Medical was formerly known as Crymed Technologies and changed its name to CSA Medical in April 2006. The company was incorporated in 1993 and is based in Lutherville Timonium, Maryland.

Sutro Biopharma, Inc.

Series C in 2010
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

AavantiBio

Series A in 2020
AavantiBio, Inc. engages in developing gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. It focuses on Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company was incorporated in 2019 and is based in Gainesville, Florida.

CellZome

Venture Round in 2004
CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs for the treatment of inflammatory diseases. It develops a pipeline of kinase inhibitors targeting inflammatory mediators as oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma. CellZome was founded in 2000 and is based in Heidelberg, Baden-Wurttemberg.

Urgent Team Holdings, Inc.

Private Placement in 2018
Urgent Team Holdings, Inc. operates urgent care centers that provide urgent and primary health care services. It offers services for patients in the areas of sprains, strains, and broken bones; muscular pain and injuries; eye irritation and eye injuries; cuts and scrapes; bites, stings, and allergic reactions; burns and infections; diarrhea, nausea, and vomiting; flu, colds, and viral illnesses; pneumonia and bronchitis; and asthma attacks. The company also offers preventative screenings/wellness services, including flu shots, physicals, immunization and vaccinations, EKGs, and osteoporosis screening, as well as blood glucose, blood pressure, and cholesterol checks; radiology, lab work and diagnostic testing, and drug and alcohol screening services; and services for employers.
Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With business and development operations based in Boston, and dedicated research capabilities in close proximity to the University of Kansas, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.

Centauri Health Solutions, Inc.

Venture Round in 2018
Centauri Health Solutions is a technology-centric company specializing in hosted software solutions, data-driven services, and data management designed specifically for risk adjustment and quality based revenue programs.

AeroCare Holdings, Inc.

Series A in 2016
AeroCare is a durable medical equipment (DME) company that provides respiratory therapy services, medical equipment, and equipment cleaning supplies. AeroCare provides equipment and services for home oxygen, nebulized respiratory medications, and sleep therapy. AeroCare's patients are most often diagnosed with diseases that make breathing very difficult such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Obstructive Sleep Apnea (OSA).

EBT Medical, Inc.

Series A in 2019
EBT Medical is a clinical-stage startup developing disruptive neuromodulation therapies for pelvic health disorders. EBT was founded based on scientific discoveries made at the University of Toronto and successfully incubated by their startup program, which has helped create over 500 companies in the last 10 years.

Adimab

Series B in 2008
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

AppRev

Merger/Acquisition in 2020
AppRev delivers industry-leading solutions that enable providers to optimize revenue cycle performance. Using cloud based software, supported by AppRev experts, providers are able to identify, quantify, resolve and measure key revenue cycle issues. AppRev's solutions combine software with consulting and include Charge Accuracy, Denials Intelligence and Pricing Analytics.

Ocular Therapeutix

Series C in 2009
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

CardioKinetix, Inc.

Series F in 2016
CardioKinetix, Inc. develops transcatheter implants. Its portfolio includes Parachute, a ventricular partitioning device that intends to treat heart failure resulting from a heart attack in patients by improving the overall cardiac function. The company’s Parachute is deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. It serves customers primarily in the United States, France, Germany, Latvia, Portugal, Serbia, Slovenia, the Netherlands, and the United Kingdom. The company was incorporated in 2002 and is headquartered in Menlo Park, California.

Allos Therapeutics

Seed Round in 1994
Allos Therapeutics is a biopharmaceutical company that develops and commercializes anti-cancer therapeutics. FOLOTYN, the company’s main product is a folate analogue metabolic inhibitor design to accumulate preferentially in cancer cells so as to cause cell death. Allos Therapeutics was founded in 1992 and is headquartered in Westminster, Colorado.  As of September 4, 2012, Allos Therapeutics operates as a subsidiary of Spectrum Pharmaceuticals, Inc.

Aptiv Solutions

Seed Round in 1997
Aptiv Solutions, Inc. operates as a clinical research organization that offers clinical trial services. The company also provides adaptive trial design, simulation, and execution; early phase development consulting; pre clinical development; and drug development services. The company also provides regulatory compliance consulting services, which include strategy development, agency advisory, legal representation, and submission management services. It also offers therapeutic services in the areas of oncology, cardiology, dermatology, respiratory, and orphan diseases. Further, the company develops AptivAdvantage, an integrated technology platform for the implementation and execution of adaptive clinical trials. Aptiv Solutions, Inc. was formerly known as Averion International Corp. and changed its name to Aptiv Solutions, Inc. in February 2011. The company was founded in 1983 and is based in Reston, Virginia with an office in Durham, North Carolina.

PanOptica

Series B in 2016
PanOptica, Inc., develops topical eye drop for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. The company offers PAN-90806, a small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. It serves pharmaceutical companies. The company was founded in 2009 and is based in Mount Arlington, New Jersey.

Axys Pharmaceuticals

Venture Round in 2004
AXYS Pharmaceuticals, Inc. is engaged in discovery, design, and development of therapeutic small molecules that addressed significant markets with major unmet medical needs. It collaborates with large pharmaceutical companies in discovering therapeutics for chronic diseases. In addition, it also discovers and develops therapeutics for the treatment of various types of cancer and other specialty therapeutic opportunities. AXYS Pharmaceuticals, Inc. was formerly known as Arris Pharmaceuticals, Incorporated. The company is based in South San Francisco, California. As of November 16, 2001, AXYS Pharmaceuticals, Inc. operates as a subsidiary of Celera Corporation.

Socios Mayores en Salud

Venture Round in 2006
Socios Mayores en Salud, Inc., doing business as American Health Medicare, provides health plans.

Ocular Therapeutix

Series C in 2011
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Homecare Homebase

Venture Round in 2005
Homecare Homebase, based in Dallas, Texas, is a leading healthcare software company serving the technology needs of the fast growing homecare and hospice industry. Twice named Best In KLAS for Homecare by KLAS in 2010 and 2011 “Best in KLAS Awards: Software & Services” report, Homecare Homebase offers a comprehensive integrated cloud-based software solution to improve the clinical, operational and financial success of homecare and hospice agencies. Homecare Homebase enables real-time, wireless information exchange and communication between office staff, field staff and physicians; automates workflow processes; enables accurate billing through numerous integrated checks and balances; and, provides powerful management reporting via a back-office data analysis tool that ties together all agency operational information. Founded by industry veterans in 1999, every aspect of the Homecare Homebase system was developed to be user-friendly, flexible and customizable to specific agency needs.

Altura Medical

Series A in 2010
Altura Medical is an emerging medical device company based in Menlo Park, CA that is developing a next generation endograft technology to treat abdominal aortic aneurysms (“AAA”) and other related disease states. Development of the company’s highly differentiated technology is led by an experienced management team and supported by a prestigious syndicate of venture capital investors.

Bardy Diagnostics

Series A in 2017
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

AVROBIO, Inc.

Private Placement in 2018
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.

Triangle Pharmaceuticals

Venture Round in 1999
Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.

PanOptica

Series A in 2011
PanOptica, Inc., develops topical eye drop for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. The company offers PAN-90806, a small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. It serves pharmaceutical companies. The company was founded in 2009 and is based in Mount Arlington, New Jersey.

Cerevance

Private Placement in 2020
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

LeukoSite

Post in 1997
LeukoSite develops small molecule and monoclonal antibody treatment and care for inflammatory, autoimmune, cancer applications, and viral diseases. Its product portfolio includes CAMPATH, a treatment intended for the cure of chronic lymphocytic leukemia, LDP-977 for the treatment of bronchial asthma, LDP-02 for inflammatory bowel disease, and more. LeukoSite also had nine partner-funded research and discovery programs.

KalVista Pharmaceuticals

Series B in 2015
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSK”). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.

NeoVista

Series E in 2011
NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

PanOptica

Series B in 2017
PanOptica, Inc., develops topical eye drop for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. The company offers PAN-90806, a small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. It serves pharmaceutical companies. The company was founded in 2009 and is based in Mount Arlington, New Jersey.

Leiter's

Seed Round in 2020
Leiter's Cambrian Park Drugs, Inc., doing business as Leiters Compounding Pharmacy Inc., manufactures and sells pharmaceutical care and specialty compounding products for universities, hospitals, civic organizations, health organizations, and health maintenance organizations in the United States. The company offers ophthalmology and ophthalmic solutions; and autologous serums, avastin products, Brilliant Blue G products, erectile dysfunction products, intravitreal injections, lidocaine/phenylephrine PF products, mitomycin, and moxifloxacin. It allows customers to order products online. The company was founded in 1925 and is based in San Jose, California.

Catabasis Pharmaceuticals

Series B in 2013
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

Perfuze

Series A in 2022
Perfuze develops technology to treat acute ischemic stroke. The company was founded in 2018 and is based in Galway, Ireland.

Sutro Biopharma, Inc.

Series E in 2018
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Maestro Health

Series A in 2016
Founded in 2013, Maestro Health is an American employee benefits company that provides integrated one-stop shopping experiences, along with private-labeled exchange solutions. It also offers employee health and benefits management solutions for brokers, small employers, and Fortune 1000 organizations. It combines private exchange, benefits administration, enrollment, self-insurance, healthcare savings account administration, and components on its integrated mobile and web platform, maestroEDGE. The company owns and operates a proprietary private exchange and medical TPA, which allows the streamlined integration of care management to drive down costs for employers.

Bardy Diagnostics

Private Placement in 2016
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.
Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Third Wave Technologies

Venture Round in 1997
Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. The company offers products based proprietary Invader chemistry, a technology used in women's health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company's analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe. The company was founded in 1993 and is headquartered in Madison, Wisconsin. As of July 23, 2008, Third Wave Technologies Inc. operates as a subsidiary of Hologic Inc.

AcuFocus, Inc.

Venture Round in 2014
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA. Its products are used in eye care centers in the United States, Asia, and Europe. Acufocus, Inc. was founded in 2001 and is based in Irvine, California.

GlycoFi Inc.

Series C in 2005
GlycoFi is a biotech firm that develops biotherapeutics based on the glycan optimization technology. The firm aims to develop its own pipeline of therapeutic proteins and team with other drug-makers to develop products. GlycoFi has developed a protein manufacturing process using yeast-based glycolysation where the resulting proteins can be used in drug development. GlycoFi was incorporated in 2000 and is based in Lebanon, New Hampshire. As of June 6, 2006, GlycoFi, Inc. operates as a subsidiary of Merck & Co. Inc.

Autifony Therapeutics Limited

Funding Round in 2011
Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

NovaLign Orthopaedics

Series B in 2009
NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

Delenex Therapeutics

Series A in 2011
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Sutro Biopharma, Inc.

Series B in 2007
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

ENDOTRONIX

Private Placement in 2016
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.
Karus Therapeutics Limited is a biopharmaceutical company that develops medicines for cancer. Its portfolio includes orally-active small molecule drugs, including KA2237, a dual-selective inhibitor of PI3K isoforms, such as p110ß and p110d for treating hematological and solid tumors; and KA2507 (HDAC6) for PD-L1 expressing tumors. The company was incorporated in 2005 and is based in Oxfordshire, United Kingdom.

Sutro Biopharma, Inc.

Series B in 2009
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

ReShape Lifesciences

Series D in 2015
ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

Bardy Diagnostics

Private Placement in 2019
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

ValenTx, Inc.

Series B in 2009
ValenTx, Inc., a medical device company, develops therapy solutions to treat patients with obesity and obesity-related metabolic disorders. The company’s portfolio includes endoluminal bypass therapy that mimics the permanent anatomical changes made by the Roux-en-Y gastric bypass procedure with an adjustable, removable, and replaceable device. Its therapy solutions focus on treating type-2 diabetes and hypertension. The company was founded in 2002 and is based in Maple Grove, Minnesota.

Akriveia Therapeutics

Series C in 2021
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Halscion, Inc.

Debt Financing in 2012
HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.

CardioFocus

Series C in 2001
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, and investigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias. CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts.

Nimbus Therapeutics

Venture Round in 2022
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Ophthotech

Series A in 2007
Ophthotech Corporation, a biopharmaceutical company, develops various therapeutics to treat diseases of the eye. It is developing Fovista, which has completed Phase IIb clinical trials for use in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (wet AMD); and ARC1905, a potent and selective inhibitor of complement factor C5 that has completed Phase I/IIa clinical trials to treat wet AMD. The company was founded in 2007 and is headquartered in New York, New York.

Bicycle Therapeutics

Series A in 2014
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

MicroMed Technology

Series D in 2002
According to American Heart Association statistics, 20,000-40,000 patients in the United States would benefit from a heart transplant. The MicroMed DeBakey VAD®, jointly developed with Dr. Michael DeBakey, Dr. George Noon and the National Aeronautics and Space Administration (NASA), has the potential to keep many of these people alive until a donor heart becomes available. Weighing less than four ounces, the device is silent and is approximately 1/10 the size of other pulsatile products on the market. The MicroMed DeBakey VAD® is designed to be a lower-cost, less invasive alternative to the commercially available, larger ventricular assist devices (VADs).

EBT Medical, Inc.

Private Placement in 2019
EBT Medical is a clinical-stage startup developing disruptive neuromodulation therapies for pelvic health disorders. EBT was founded based on scientific discoveries made at the University of Toronto and successfully incubated by their startup program, which has helped create over 500 companies in the last 10 years.

Catabasis Pharmaceuticals

Series A in 2010
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

CardioFocus

Debt Financing in 2016
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, and investigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias. CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts.
SUN Behavioral Health, Inc. operates hospitals that provide various behavioral health services to children, youth, adults, and seniors. The company’s services include inpatient psychiatric and substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. It also serves women, and active duty and veteran military persons. The company is based in Red Bank, New Jersey. SUN Behavioral Health, Inc. operates as a subsidiary of SUN Behavioral HoldCo, LLC.

Sadra Medical

Series C in 2009
Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease. Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today. Sadra Medical, a subsidiary of Boston Scientific.

Clarify Medical

Private Placement in 2019
Clarify Medical, Inc. develops home therapy solutions for chronic skin treatments. It offers The Clarify mobile ultra violet B treatment system, an investigational device for use in treating plaque psoriasis, eczema, and vitiligo; and Home Light Therapy System, a home phototherapy system for the treatment of psoriasis, vitiligo, and eczema. Clarify Medical, Inc. was formerly known as Skylit Medical, Inc. and changed its name to Clarify Medical, Inc. in September 2016. The company was incorporated in 2014 and is based in San Diego, California.

Bardy Diagnostics

Private Placement in 2018
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

CardioMind

Venture Round in 2008
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

EBR Systems

Venture Round in 2009
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

Mpex Pharmaceuticals

Series B in 2005
Mpex Pharmaceuticals is a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, with a particular focus on gram-negative organisms. The Company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

Adimab

Series A in 2007
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

AeroCare Holdings, Inc.

Private Equity Round in 2019
AeroCare is a durable medical equipment (DME) company that provides respiratory therapy services, medical equipment, and equipment cleaning supplies. AeroCare provides equipment and services for home oxygen, nebulized respiratory medications, and sleep therapy. AeroCare's patients are most often diagnosed with diseases that make breathing very difficult such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Obstructive Sleep Apnea (OSA).

Clarify Medical

Series A in 2019
Clarify Medical, Inc. develops home therapy solutions for chronic skin treatments. It offers The Clarify mobile ultra violet B treatment system, an investigational device for use in treating plaque psoriasis, eczema, and vitiligo; and Home Light Therapy System, a home phototherapy system for the treatment of psoriasis, vitiligo, and eczema. Clarify Medical, Inc. was formerly known as Skylit Medical, Inc. and changed its name to Clarify Medical, Inc. in September 2016. The company was incorporated in 2014 and is based in San Diego, California.